Pulmonary Drug Delivery Systems Market Growth and Size 2031

Pulmonary Drug Delivery Systems Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Dry Powder Inhalers, Nebulizers, and Metered Dose Inhalers), Indication (Asthma, Chronic Obstructive Pulmonary Diseases, Cystic Fibrosis, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce), End User (Hospitals & Clinics and Homecare), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)

  • Report Code : TIPHE100001256
  • Category : Medical Device
  • No. of Pages : 150
Buy Now

The pulmonary drug delivery systems market size is projected to reach US$ 73.14 billion by 2031 from US$ 49.71 billion in 2023; the market is estimated to record a CAGR of 4.9% during 2023–2031.

Market Insights and Analyst View:

Pulmonary drug delivery systems are used to deliver aerosols directly to epithelial cells and respiratory epithelium through inhalation. The systems include devices such as inhalers and nebulizers for delivering drugs to the lungs to treat patients affected by respiratory diseases. Pulmonary drug delivery devices are based on diverse delivery mechanisms and contain various drug formulations. Asthma, chronic obstructive pulmonary diseases (COPD), acute respiratory tract infections, allergic rhinitis, and cystic fibrosis are major respiratory diseases that require the use of drug delivery devices. The increasing burden of respiratory diseases and growing strategic initiatives by companies favor the pulmonary drug delivery systems market growth. The pulmonary drug delivery systems market trends include the advancements in inhaler technologies that will favor the growth of the market in the future.

Growth Drivers:

Companies operating in the pulmonary drug delivery systems market constantly focus on strategic developments such as collaboration, agreements, partnerships, and new product launches. These strategies help them improve their sales, increase their geographic reach, and enhance their capacities to serve a greater than existing customer base. The new product launches are mainly directed toward increased security, user-friendly features, better dosing capabilities, etc., to attract a large patient base. Following are a few noteworthy developments in the pulmonary drug delivery systems market:

  • In September 2021, BreatheSuite Inc. received 510(K) clearances from the US Food and Drug Administration (FDA) for its BreatheSuite metered-dose inhaler V1 device for prescription and over-the-counter use. The BreatheSuite V1 transforms existing metered-dose inhalers into smart inhalers by automatically and accurately monitoring and providing feedback on inhaler adherence and technique for asthma and COPD patients.
  • In June 2021, Glenmark Pharmaceuticals Ltd launched Tiogiva, a bioequivalent version of Tiotropium Bromide dry powder inhaler, in the UK to treat COPD.
  • In April 2021, KINDEVA DRUG DELIVERY collaborated with Cambridge Healthcare Innovations Limited (CHI) to develop and commercialize CHI’s αeolus dry-powder inhaler (DPI) platform technology.
  • In December 2020, AireHealth, an innovative digital health company, received 510(k) clearance for its connected nebulizer. The device is a portable and electronic vibrating mesh nebulizer. It is designed to nebulize liquid medications for inhalation by a patient. It is marketed under the brand name VitalMed.
  • In September 2020, GlaxoSmithKline plc and Innoviva, Inc. received FDA approval for Trelegy Ellipta as the first once-daily single inhaler triple therapy to treat asthma and COPD patients aged 18 years and above in the US.

Thus, the growing number of strategic developments and product launches by the companies to remain competitive in the market propels the pulmonary drug delivery systems market growth.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Pulmonary Drug Delivery Systems Market: Strategic Insights

pulmonary-drug-delivery-devices-systems-market
Market Size Value inUS$ 49.71 billion in 2023
Market Size Value byUS$ 73.14 billion by 2031
Growth rateCAGR of 4.9% from 2023 to 2031
Forecast Period2023-2031
Base Year2023
Analyst Image

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

Report Segmentation and Scope:

The pulmonary drug delivery systems market analysis has been carried out by considering the following segments: product, indication, distribution channel, end user, and geography. In terms of product, the market is segmented into dry powder inhalers, nebulizers, and metered dose inhalers. By indication, the market is classified into chronic obstructive pulmonary diseases, asthma, cystic fibrosis, and others. Based on distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, and e-commerce. Based on end user, the market is bifurcated into hospitals & clinics and homecare. The scope of pulmonary drug delivery systems market report covers North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:

The pulmonary drug delivery systems market, by product, is categorized into dry powder inhalers, nebulizers, and metered dose inhalers. The dry powder inhalers segment held a significant market share in 2023. It is anticipated to record the highest CAGR in the market during 2023–2031.

In terms of indication, the pulmonary drug delivery systems market is classified into chronic obstructive pulmonary diseases, asthma, cystic fibrosis, and others. The chronic obstructive pulmonary diseases segment held a significant market share in 2023 and is projected to register the highest CAGR during 2023–2031.

Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment held a significant pulmonary drug delivery systems market share in 2023. The e-commerce segment is expected to register the highest CAGR during 2023–2031.

Based on end user, the pulmonary drug delivery systems market is bifurcated into hospitals & clinics and homecare. The hospitals & clinics segment held a significant market share in 2023. The homecare segment is estimated to register a higher CAGR during 2023–2031.

Regional Analysis:

Geographically, the pulmonary drug delivery systems market is segmented into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2023, North America held a significant share of the market. In 2023, the US held the largest share of the market in the region. The market growth in North America is attributed to the rising incidence of respiratory diseases such as asthma, COPD, and others; increasing geriatric population; growing demand for diagnostic devices; and the strong presence of key market players. According to the Centers for Disease Control and Prevention (CDC), 2020, about 5.0% of adults are diagnosed with COPD or chronic bronchitis in the US. About 25 million people are affected by asthma, and 14.8 million have COPD. In addition, the Canadian Nurse Association estimated that ~3 million people in Canada suffer from one of serious respiratory diseases such as COPD, cystic fibrosis, asthma, and occupational lung diseases.

According to the Canadian Lung Association, respiratory diseases are responsible for the third highest share of hospitalizations, and approximately one in five people in Canada suffer from serious respiratory diseases, such as asthma, COPD, lung cancer, tuberculosis, cystic fibrosis, and respiratory distress syndrome. The rising number of patients suffering from various respiratory diseases propels the demand for innovative and effective pulmonary drug delivery systems such as metered dose inhalers or nebulizers.

Pulmonary Drug Delivery Systems Market Report Scope

Industry Developments and Future Opportunities:

The pulmonary drug delivery systems market report includes company positioning and concentration to evaluate the performance of competitors in the market. As per company press releases, below are a few initiatives taken by key players operating in the market:

  • In March 2021, PARI Pharma GmbH received the authorization of LAMIRA Nebulizer System for delivery of Insmed’s drug product ARIKAYCE (amikacin liposome inhalation suspension) in Japan. Insmed received approval for ARIKAYCE by Japan’s Ministry of Health, Labour, and Welfare in March 2021. The approval of ARIKAYCE in the country follows earlier approvals in the US and Europe.
  • In December 2020, the European Commission approved AstraZeneca’s Trixeo Aerosphere in the European Union for COPD. It is used in the treatment of adult patients suffering from moderate to severe COPD. Trixeo Aerosphere is a single-inhaler, fixed-dose triple-combination of formoterol fumarate, glycopyrronium bromide, with budesonide, and an inhaled corticosteroid, and delivered in a pressurized metered-dose inhaler.

Competitive Landscape and Key Companies:

The pulmonary drug delivery systems market forecast can help stakeholders plan their growth strategies. AstraZeneca, GlaxoSmithKline Plc, Novartis AG, Koninklijke Philips NV, Boehringer Ingelheim International GmbH, Cipla Inc., OMRON Corp., PARI GmbH, Glenmark Pharmaceuticals, and Gilbert Technologies are among the prominent players in the market. These companies focus on introducing new high-tech products, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide.

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Product, Indication, Distribution Channel, End User, and Geography

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is the driving and restraining factors for the pulmonary drug delivery systems market?

The factors driving the growth of the pulmonary drug delivery systems market include the increasing burden of respiratory diseases and growing strategic initiatives by companies. However, regulatory issues associated with the approval of pulmonary drug delivery systems hampers the growth of the pulmonary drug delivery systems market.

Which segment is dominating the pulmonary drug delivery systems market?

The global pulmonary drug delivery systems market is segmented based on product, indication, distribution channel, and end user. The pulmonary drug delivery systems market, by product, is categorized into dry powder inhalers, nebulizers, and metered dose inhalers. The dry powder inhalers segment held a significant market share in 2023 and is anticipated to record the highest CAGR in the market during 2023–2031.

What was the estimated pulmonary drug delivery systems market size in 2023?

The pulmonary drug delivery systems market was valued at US$ 49.71 billion in 2023.

What are the growth estimates for the pulmonary drug delivery systems market till 2031?

The pulmonary drug delivery systems market is expected to be valued at US$ 73.14 billion in 2031.

Who are the major players in the pulmonary drug delivery systems market?

The pulmonary drug delivery systems market majorly consists of the players, including AstraZeneca, GlaxoSmithKline Plc, Novartis AG, Koninklijke Philips NV, Boehringer Ingelheim International GmbH, Cipla Inc., OMRON Corp., PARI GmbH, Glenmark Pharmaceuticals, and Gilbert Technologies.

What is pulmonary drug delivery systems?

Pulmonary drug delivery refers to the systems that target the delivery of aerosols directly to epithelial cells and respiratory epithelium through inhalation. These systems deliver the drug to the lungs to treat respiratory diseases. It is one of the most preferred drug delivery routes and a noninvasive technique with a large surface area of absorption and blood circulation.

The List of Companies - Pulmonary Drug Delivery Systems Market

  1. AstraZeneca
  2. GlaxoSmithKline Plc
  3. Novartis AG
  4. Koninklijke Philips NV
  5. Boehringer Ingelheim International GmbH
  6. Cipla Inc
  7. OMRON Corp.
  8. PARI GmbH
  9. Glenmark Pharmaceuticals
  10. Gilbert Technologies

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Pulmonary Drug Delivery Systems Market